De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Adicet Bio Beheer

Beheer criteriumcontroles 2/4

De CEO Adicet Bio's is Chen Schor, benoemd in Sep2020, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.97M, bestaande uit 10.1% salaris en 89.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.16% van de aandelen van het bedrijf, ter waarde $ 194.25K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 3.4 jaar.

Belangrijke informatie

Chen Schor

Algemeen directeur

US$6.0m

Totale compensatie

Percentage CEO-salaris	10.1%
Dienstverband CEO	4.1yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	3.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chen Schor's beloning veranderd ten opzichte van Adicet Bio's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$137m
Mar 31 2024	n/a	n/a	-US$140m
Dec 31 2023	n/a	n/a	-US$143m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$4m	US$562k	-US$70m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$10m	US$536k	-US$62m
Sep 30 2021	n/a	n/a	-US$55m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$11m	US$499k	-US$37m

Compensatie versus markt: De totale vergoeding ($USD 5.97M ) Chen } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 373.18K ).

Compensatie versus inkomsten: De vergoeding van Chen is gestegen terwijl het bedrijf verliesgevend is.

CEO

Chen Schor (52 yo)

4.1yrs

Tenure

US$5,973,807

Compensatie

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Chen Schor	CEO, President & Director	4.1yrs	US$5.97m	0.16% $ 195.6k
Aya Jakobovits	Founder & Independent Director	no data	US$240.29k	1.04% $ 1.2m
Brian Harvey	Chief Financial Officer	4.1yrs	US$2.13m	0.068% $ 81.3k
Donald Healey	Chief Technology Officer	4yrs	US$2.09m	0.043% $ 51.1k
Blake Aftab	Senior VP & Chief Scientific Officer	3.5yrs	US$2.48m	0.031% $ 36.8k
Amy Locke	Chief Human Resource Officer	2.8yrs	geen gegevens	geen gegevens
Francesco Galimi	Chief Medical Officer & Senior VP	4.1yrs	US$1.99m	0.092% $ 109.5k
Nancy Boman	Senior VP & Chief Regulatory Officer	1.9yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0HX7 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Chen Schor	CEO, President & Director	4.1yrs	US$5.97m	0.16% $ 195.6k
Aya Jakobovits	Founder & Independent Director	4.1yrs	US$240.29k	1.04% $ 1.2m
Carl Gordon	Independent Chairman	4.1yrs	US$275.29k	0.0072% $ 8.6k
Steve Dubin	Independent Director	4.1yrs	US$254.29k	0.013% $ 15.8k
Andrew Sinclair	Independent Director	3.6yrs	US$255.29k	0.0072% $ 8.6k
Jeffrey Chodakewitz	Independent Director	4.1yrs	US$240.29k	0.0072% $ 8.6k
Marco Davila	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Lloyd Klickstein	Director	less than a year	US$2.90m	0.12% $ 148.9k
Michael Kalos	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Saul Priceman	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Constantine Mitsiades	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens
Alice Bertaina	Member of Scientific Advisory Board	3.3yrs	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0HX7 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Adicet Bio Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Revenue beats expectations

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd